A confirmatory trial of Vincristine liposomal (Marqibo®)
Phase of Trial: Phase III
Latest Information Update: 15 Sep 2017
At a glance
- Drugs Vincristine (Primary)
- Indications Cancer; Multiple myeloma; Non-Hodgkin's lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Registrational; Therapeutic Use
- 15 Sep 2017 New trial record
- 07 Sep 2017 According to a CASI Pharmaceuticals media release, the confirmatory trial is required as part of the registration process for the import drug registration.
- 07 Sep 2017 According to a CASI Pharmaceuticals media release, the CFDA review of the import drug clinical trial application (CTA) for Marqibo is in process and the company believes that the CFDA will complete it's review in the next four to six months and expects to initiate the confirmatory trial within six months after CTA approval.